八国淋球菌四环素耐药率极高,多西环素暴露后预防或难减淋病负担
研究分析2021-2024年WHO EGASP八国2993株淋球菌,四环素耐药率按EUCAST和CLSI折点分别为92.2%和80.6%,按minocycline-PEP及tetM高耐药折点分别为77.3%和74.3%。作者结论:多西环素-PEP不太可能显著减少这些国家的淋病病例,并可能快速选择出额外耐药株及MDR/XDR株。
要点
- 八国淋球菌四环素耐药率按EUCAST折点为92.2%,按CLSI折点为80.6%。
- 按minocycline-PEP折点和tetM高耐药折点,耐药率分别为77.3%和74.3%。
- 作者认为多西环素-PEP不太可能显著降低这些国家的淋病病例。
核心结论
- 八国淋球菌四环素耐药率极高(不依赖所用耐药折点),多西环素-PEP不太可能显著减少这些国家的淋病病例。
- 多西环素-PEP可能快速选择出额外的低水平和高水平四环素耐药淋球菌株及MDR/XDR株,因这些菌株大多对四环素耐药。
研究设计与样本
- 研究分析2021-2024年WHO EGASP八国(柬埔寨、印度尼西亚、马拉维、菲律宾、南非、泰国、乌干达、越南)尿道分泌物男性培养的淋球菌分离株2993株。
- 用Etest测定四环素MIC(mg/L)。
主要发现
- 八国合计淋球菌四环素耐药率按EUCAST折点(MIC > 0.5 mg/L)为92.2%(国家范围83.5%-99.6%),按CLSI折点(MIC > 1 mg/L)为80.6%(66.3%-98.6%)。
- 按既往minocycline-PEP耐药折点(MIC > 2 mg/L)耐药率为77.3%(47.4%-98.6%),按高水平质粒(tetM)介导四环素耐药折点(MIC > 8 mg/L)为74.3%(31.3%-98.6%)。
关键数值与推荐
- EUCAST临床耐药折点:四环素MIC > 0.5 mg/L,八国耐药率92.2%(83.5%-99.6%)。
- CLSI临床耐药折点:四环素MIC > 1 mg/L,八国耐药率80.6%(66.3%-98.6%)。
- 既往minocycline-PEP耐药折点:MIC > 2 mg/L,耐药率77.3%(47.4%-98.6%)。
- 高水平质粒(tetM)介导四环素耐药折点:MIC > 8 mg/L,耐药率74.3%(31.3%-98.6%)。
临床怎么用
- 作者结论认为,基于八国极高的淋球菌四环素耐药率,多西环素-PEP不太可能显著减少这些国家的淋病病例。
- 作者指出多西环素-PEP可能快速选择出额外四环素耐药(低水平和高水平)淋球菌株及MDR/XDR株。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Doxycycline post-exposure prophylaxis (doxycycline-PEP) can reduce incident cases of syphilis, chlamydia and possibly gonorrhoea especially among men who have sex with men with recent bacterial sexually transmitted infections (STIs). Owing to potential implementation of doxycycline-PEP internationally, global tetracycline/doxycycline resistance data for contemporary Neisseria gonorrhoeae isolates has become imperative. We report tetracycline resistance data for gonococcal isolates (n = 2993) from eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) countries in three WHO regions in 2021-2024, i.e. to estimate potential impact of doxycycline-PEP on the incident gonorrhoea cases in these WHO EGASP countries. METHODS: WHO EGASP isolates cultured from men with urethral discharge in Cambodia (n = 482), Indonesia (n = 101), Malawi (n = 121), The Philippines (n = 843), South Africa (n = 597), Thailand (n = 250), Uganda (n = 350) and Vietnam (n = 249) in 2021-2024 were examined. MICs (mg/L) of tetracycline were determined using Etest. RESULTS: The tetracycline resistance (range) using the current EUCAST (MIC > 0.5 mg/L) and CLSI (MIC > 1 mg/L) clinical resistance breakpoints in the eight WHO EGASP countries was 92.2% (83.5%-99.6%) and 80.6% (66.3%-98.6%), respectively. Using a previous minocycline-PEP resistance breakpoint (MIC > 2 mg/L) and breakpoint for high-level plasmid (tetM)-mediated tetracycline resistance (MIC > 8 mg/L), the tetracycline resistance (range) was 77.3% (47.4%-98.6%) and 74.3% (31.3%-98.6%), respectively. CONCLUSIONS: The exceedingly high levels of gonococcal tetracycline resistance (independent of resistance breakpoint used) in the eight WHO EGASP countries elucidate that doxycycline-PEP will unlikely significantly reduce the gonorrhoea cases in these countries. Furthermore, doxycycline-PEP might rapidly select for additional gonococcal strains with tetracycline resistance (low- and high-level) and MDR/XDR strains, i.e. because these strains are mostly resistant to tetracycline.
引用
- Schröder D, Cherdtrakulkiat T, Doanh LH, et al. Exceedingly high levels of tetracycline resistance in Neisseria gonorrhoeae in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-2024-doxycycline post-exposure prophylaxis will unlikely impact gonorrhoea burdens. J Antimicrob Chemother. 2025. PMID: 40099718. doi:10.1093/jac/dkaf066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。